Needham analyst Stephen raised his price target on Genomic Health to $97 and kept his Strong Buy rating after its Q4 results and higher than expected FY19 earnings guidance. The analyst notes that the company’s financial model offers “significant operating leverage” that was “clearly demonstrated” in 2018 and sees potential for earnings growth to persist this year thanks to the better than expected testing volumes of its Oncotype breast cancer test product.
https://thefly.com/landingPageNews.php?id=2867819
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.